Progress in the Treatment of Refractory Myasthenia Gravis - PubMed
3 hours ago
- #autoimmune disorder
- #myasthenia gravis
- #targeted therapy
- Myasthenia gravis (MG) is an autoimmune disorder affecting neuromuscular junction transmission.
- Approximately 10% of MG patients develop refractory MG (RMG), unresponsive to standard therapies.
- New treatments for RMG include targeted biologics, B-cell depletion therapy, and CAR-T cell therapy.
- Complement inhibitors and Fc receptor antagonists are among the promising targeted biologics.
- The study reviews RMG treatment progress to support clinical decision-making and future research.